Mark Faghy

📢 Our paper is published in Oxford Open Immunology: The ERASE_LC trial evaluated whether a 5-day course of intravenous remdesivir is feasible, safe, and acceptable for people living with Long COVID. This is the first study to specifically examine remdesivir as a treatment for LC.

This provides an important foundation for the next generation of Long COVID treatment trials. 📄 Read the paper: doi.org/10.1093/oxfi... @derbyuni.bsky.social @exeter.ac.uk @lindsayskipper.bsky.social @longcovidphysio.bsky.social @longcoviduk.bsky.social @longcovidadvoc.com @1goodtern.bsky.social

📢 Our paper is published in Oxford Open Immunology: The ERASE_LC trial evaluated whether a 5-day course of intravenous remdesivir is feasible, safe, and acceptable for people living with Long COVID. This is the first study to specifically examine remdesivir as a treatment for LC.

These findings should be interpreted cautiously, but they provide a strong rationale for further investigation.

📢 Our paper is published in Oxford Open Immunology: The ERASE_LC trial evaluated whether a 5-day course of intravenous remdesivir is feasible, safe, and acceptable for people living with Long COVID. This is the first study to specifically examine remdesivir as a treatment for LC.

🛡️ Safety was a primary consideration. There were no severe adverse reactions were reported, and almost all participants successfully completed treatment. This is an important first step in determining whether IV antiviral treatment strategies can be tested in larger trials.

📢 Our paper is published in Oxford Open Immunology: The ERASE_LC trial evaluated whether a 5-day course of intravenous remdesivir is feasible, safe, and acceptable for people living with Long COVID. This is the first study to specifically examine remdesivir as a treatment for LC.

🔬 We recruited 73 adults with confirmed Long COVID across two UK sites. Key feasibility findings: ✅ 97% completed the full 5-day remdesivir course ✅ 96% completed follow-up assessments ✅ High engagement with outcome measures and symptom tracking

📢 Our paper is published in Oxford Open Immunology: The ERASE_LC trial evaluated whether a 5-day course of intravenous remdesivir is feasible, safe, and acceptable for people living with Long COVID. This is the first study to specifically examine remdesivir as a treatment for LC.

📢 Participants needed for Long COVID research I'm helping an MSc student recruit adults living with Long COVID for an important study exploring experiences of rehabilitation and recovery. 🔗 app.onlinesurveys.jisc.ac.uk/s/lboro/long...

Not eligible yourself? A repost could make a huge difference by helping this survey reach people with lived experience of Long COVID. Thank you for supporting patient-centred research and the next generation of health researchers. 💙 #LongCOVID #LongCovidResearch #Rehabilitation #PatientVoice

📢 Participants needed for Long COVID research I'm helping an MSc student recruit adults living with Long COVID for an important study exploring experiences of rehabilitation and recovery. 🔗 app.onlinesurveys.jisc.ac.uk/s/lboro/long...

The study, Factors Influencing Experiences of Rehabilitation Among Adults with Long COVID: An Explanatory Sequential Mixed-Methods Study, aims to better understand what helps, what hinders, and how rehabilitation services are experienced by people with Long COVID.

Our new paper is here: Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID www.nature.com/articles/s43...

7️⃣ Take‑home message Long COVID is not a single disease but a complex, multisystem condition. Advancing care will depend on mechanism‑driven research, collaboration across disciplines, and sustained long‑term investment.

Our new paper is here: Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID www.nature.com/articles/s43...

5️⃣ This matters because.. Without a clear mechanistic understanding, progress on diagnostics, targeted treatments, and clinical trials remains slow and fragmented.

Our new paper is here: Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID www.nature.com/articles/s43...

3️⃣ Key mechanistic areas covered 🦠 Viral persistence and reservoirs 🧬 Immune dysregulation & chronic inflammation 🧠 Neurological and neurocognitive mechanisms 🫀 Cardiovascular and endothelial dysfunction ⚡ Mitochondrial and metabolic impairment 🧪 Autoimmunity and microclot hypotheses

Our new paper is here: Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID www.nature.com/articles/s43...

1️⃣ Aim This review aims to synthesise current evidence on the mechanisms and pathophysiology underlying long COVID, highlighting what is known, what remains uncertain, and why progress has been challenging.

Sorry for the silence: The ERASE-LC trial is making steady progress. All participants have now received their infusions of remdesivir and completed their post-treatment testing.

Once the results have been fully analysed and then checked by other independent researchers (a process called peer review) we will let you know the outcome. This process takes a long time.

Sorry for the silence: The ERASE-LC trial is making steady progress. All participants have now received their infusions of remdesivir and completed their post-treatment testing.